FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Coartem clears FDA for acute, uncomplicated malaria; agency finds it effective in regions where people are resistant to chloroquine.